Earnings Call · Q4 FY2021·2022-03-17

Q4 21EPS +3.57%·Rev n/aQ3 21EPS -8.00%·Rev n/aQ2 21EPS -21.74%·Rev n/aQ1 21EPS +3.85%·Rev n/a⚠ consensus missing

Aldeyra Therapeutics, Inc. ALDX

Joshua Reed — Chief Financial Officer

Todd Brady — President and Chief Executive Officer

+16.3%1d on move date+15.0% vs SPY3d+14.6%5d+13.4%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALDX calls or request research access.

More ALDX calls Browse calls Request research access